Intermittent Claudication Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

February 2022 | 37 pages | ID: ID8C3BF91485EN
Global Markets Direct

Abstracts

Intermittent Claudication Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Intermittent Claudication Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Intermittent Claudication (Cardiovascular) pipeline landscape.

Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood to leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs and sores or wounds on the lower limb that heal slowly, poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age and family history.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Intermittent Claudication Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Intermittent Claudication (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Intermittent Claudication (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 1 respectively.

Intermittent Claudication (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Intermittent Claudication (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Intermittent Claudication (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Intermittent Claudication (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Intermittent Claudication (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Intermittent Claudication (Cardiovascular)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Intermittent Claudication (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Intermittent Claudication (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Intermittent Claudication - Overview
Intermittent Claudication - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Intermittent Claudication - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Intermittent Claudication - Companies Involved in Therapeutics Development
G. Pohl-Boskamp GmbH & Co KG
Helixmith Co Ltd
ID Pharma Co Ltd
Pluristem Therapeutics Inc
Intermittent Claudication - Drug Profiles
donaperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
History of Events
DVC-10101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
emiplacel - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Cardiovascular, Dermatology and Neurology - Drug Profile
Product Description
Mechanism Of Action
nitroglycerin - Drug Profile
Product Description
Mechanism Of Action
Intermittent Claudication - Dormant Projects
Intermittent Claudication - Discontinued Products
Intermittent Claudication - Product Development Milestones
Featured News & Press Releases
Nov 12, 2018: New findings from Pluristem's phase II IC study: PLX-PAD cells significantly improves blood glucose control (HbA1c) and reduce chronic inflammation
Jun 12, 2018: Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study
Jun 04, 2018: Pluristem to Announce Top-Line Results of Its Multinational Phase II Intermittent Claudication Study on June 12, 2018
Nov 29, 2017: Peer-Reviewed Article Published on Pluristems PLX-PAD Cells Mechanism of Action to Restore Blood Flow in Ischemic Tissue
May 11, 2017: CHA Biotech Announces Completion of Koreas Phase II Trial in Intermittent Claudication (IC)
Jan 12, 2017: Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication
May 16, 2016: Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial
Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications
Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea
Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel
Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study
Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells
Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study
Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany
Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Intermittent Claudication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Intermittent Claudication - Pipeline by G. Pohl-Boskamp GmbH & Co KG, 2022
Intermittent Claudication - Pipeline by Helixmith Co Ltd, 2022
Intermittent Claudication - Pipeline by ID Pharma Co Ltd, 2022
Intermittent Claudication - Pipeline by Pluristem Therapeutics Inc, 2022
Intermittent Claudication - Dormant Projects, 2022
Intermittent Claudication - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Intermittent Claudication, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022